Australian (ASX) Stock Market Forum

1AI - Algorae Pharmaceuticals

Jump to new
Joules MM1 said:
"To release data on patients in selected
groups of that trial when all data are not available
may falsely affect the
outcome of those yet to reach the one year mark"

..and the share price
Click to expand...

What they released data on a sample of their sample????
(Link is behind a subscription)
 
fiftyeight said:
What they released data on a sample of their sample????
(Link is behind a subscription)
Click to expand...

the update is basically expanding with time as it should

what some of us concluded the first time around that the lower dosage having an immediate (relative) benefit would go onto improve the further out we go
and the heaviest dose i proposed was going to cause inflammatory response, either way, regardless of cause and effect the result is inline with initial responses so remain very positive and tell me we need much larger cohort and variety of implants....afterall, each patient comes to the gig with diff extents of damage

if we got another 26 weeks out and the second patient (double dose) showed similar improvement then that would favour all the other sciences listed for major disease studies

the BOD and Dr. Snow have always been extremely conservative, dedicated to the science, which is my fave cup o tea ...
oops, i'm ranting :smuggrin:
 
still scratching my head on how the latest release is not considered price sensitive

for the phase I trial it would be good to see data for all 4 patients to see any correlative improvement in the UPDRS past 160 thru 200 weeks to see if patient 4 improved

there is such a wide chasm between the basis of data, lack of improvement and the extent ofimprovement, we could afterall be seeing patient 4 had a severe reaction to PD which coincided with the implant, meaning, without the implant we don't know if that patient was not worse for wear immediately after the implant regardless of whether the implant took place or not and we don't know if the 1st patient did not also go thru the Hawthorn* effect

as more conversations take place, force us to recognise that this whole series of implants are far from offering single target answers while offering more questions on how little is complete
we appear to keep coming back to the same suggestion: bigger trial

if a pay-out comes from Diabecell then we'll have the (part?) funding

both phase I and II offered just enough to stop the ref from the whistle

if we dont know the absolute trigger of PD and we dont know about the rate or curve of attrition, with or without the patients own input on their own state of being, then, we cannot say we know how incremental or how big the strides are for attrition or recovery ...it's a pretty big void

patient 1 in phase I and 80 dbl implant patients tell us there is wide enough positive data (versus almost no negative data) to say, all things being equal, 2018 outlook is remarkably improved on how 2017 was going to end

*if youre going to have dental surgery and the dentist improves your dental health it's not the dentists work its the patients continuous hygiene leading upto and after the dentistry that makes and keeps the improvement...in this instance if you have two patients that diverge such as 1 and 4 it is fair to speculate that 4 may have done all the wrong things for their own well-being whereas patient 1 may have been disciplined to being pro-active in all things PD assistive and be conducive to neuron stimulation ...so many variables
 
cash injection on sale to will see price spike yet not expecting a runaway based on that release
makes a basis for positive news in feb thru may on extended trial results

https://www.asx.com.au/asxpdf/20180125/pdf/43r1hb05mf241d.pdf

quick study for customer base for Diabecell
43mm in Argentina, NZ 4.7mm, Aus 24mm population

not small

out of 88 countries Aus is 7th, NZ 12th highest per head per capita, Argentina 53rd

think of the 3 regions as exclusive and protected market base

https://www.diabetes.org.uk/about_u...-by-incidence-of-type-1-diabetes-ages-0-to-14
 
fiftyeight said:
It is May, big month for results. Hopefully for all involved they are positive
Click to expand...

theyre a good cash cow at present, maybe a rto if the right company came along, the board is fairly big on ethics and morals.... and if any signif improvement in the NTcell study participants would cause a rerate ....am a fan of the bio-tech for other applications, as a logistics company many avenues
 
Some good news this morning for LCT has sent their share price north on solid volume. It's currently up 24%.
15 May 2018 – Sydney, Australia & Auckland, New Zealand – LCT has the data from the one year follow up of the 18 patients in the Phase IIb study of NTCELL® for Parkinson's disease. The Data Safety Monitoring Board has advised that there are no safety issues arising from the data.

The one year efficacy data shows a statistically significant improvement change in the Unified Parkinson's Disease Rating Scale (UPDRS Part III in the off state) in the patients who received 40 or 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery.

The study was designed to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient subgroup. The study consisted of three groups of six patients. Two patients from each group had sham surgery with no NTCELL implanted, to act as a control. Group 1 received 40 microcapsules of NTCELL implanted on each side of the brain; group 2 received 80; and group 3 received 120.

The principal investigator, Dr Barry Snow, Auckland City Hospital, says, "The treatment is safe. There are clinical signals of interest. We need to continue to monitor patients for longer to examine the clinical significance of this efficacy data."

Dr Ken Taylor, CEO of LCT, says, "We are encouraged to see efficacy data at the longer time point. We need to further analyse this encouraging result at future time points to assess NTCELL as a potential treatment for Parkinson's disease."
Click to expand...

big.chart-LCT.gif
 
LCT surging today on good news concerning its Phase IIb study of NTCELL for Parkinson's disease.
Initial analysis of the 18 month data shows a statistically significant improvement (p = <0.05) in the UPDRS in the patients who received 80 NTCELL capsules implantation to the putamen on both sides of the brain as compared to the placebo group that received sham surgery. No benefit was observed when 120 NTCELL capsules were implanted, there being evidence of inflammation which may have compromised efficacy in this group.
Click to expand...

LCT is currently up 33.33% to 6.8c and is looking like a breakout. It has breached the 6c level before on 19 October but on that day it closed at 5.9c. Today it is looking stronger and will probably close higher.

big.chart-LCT.gif
 
greggles said:
LCT surging today on good news concerning its Phase IIb study of NTCELL for Parkinson's disease.
Click to expand...

Just had a look at these …….. The science is pretty out there:eek: Description below …

NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells that are sourced from a unique herd of designated pathogen-free pigs bred from stock originally discovered in the remote sub-Antarctic Auckland Islands.

The 12 months of recent data suggests some benefit to patients but getting the dose right will take a bit more time it sounds.
 
hat tip @Assen who emailed to find LCT releasing data on the 7th .....a decent release is likely to be precursor for application for a larger study now efficacy is clearly proven with 80 implants just ahead of the 40 implants in the ph2b study .....i have not seen a similar study by a company where the updrs or updrs-ms scores improved over this or shorter time frame (with or without drug to market)



"Podcast: Parkinson's Will Double by 2040: Are We Ready?"
https://www.michaeljfox.org/foundat...st-parkinson-will-double-by-2040-are-we-ready

thought: the smoking/nicotine has already been discounted, an erroneous correlative oft-repeated yet not studied correctly, as in: patients with skin cancer are found to have typically low levels of protective vitD3, which does not discount the reverse correlation that skin cancer causes low levels of vitD3 and the same goes with the nicotine prevents less PD onset theory, rather, the hypothesis that the function governing nicotine addiction is cocomittant to a protective function that already exists with an upregulation and that people who do not have a nicotine addiction, or whom recover easily of their nicotine addiction, have a downregulation that is part of the onset of PD as a summation of those functions, not withstanding the obvious thought that smokers die younger thus taking valid data with them....

thought: the coffee idea can also be discounted on a long-term basis, even tho i agree with the gut/brain connect in so much as coffee beans can lower inflammation markers, what is also true is that coffee causes a contraction (at worse) and lack of dilation (at best) in the vascular, which to me implies, a restriction of oxygen or nitric oxide availability as a natural course of total function, which is main reason that most people who quit coffee after a prolonged period get headaches as the blood vessels expand, so short term there are, as pointed out in the podcast, some minor benefits but in the longer run there are outlier conditions waiting to trigger
 
the 7th came n went, nuthin!
we still have that update to come, altho not crucial, it would tick all the right regulatory boxes in excess of what the company thinks the regulatory authority want to see*

as reflected in the auction

*"The company is currently analysing the most recent trial data to determine
the point at which we will approach the New Zealand regulators for their view on
the likelihood of LCT being able to make NTCELL commercially available to people with Parkinson’s disease."
http://www.lctglobal.com/upload/news/2018/181115 LCT 2018 AGM Chairmans Address.pdf
 
update due monday 21st
thanks @Assen

i guess the only significant annoc is in May this year....long way away but it'll be significant enough to determin company outlook for a couple of years:

Future development path
In May 2019 the 24 month efficacy data for all three dose groups will be available. At each data milestone we review the findings with our NTCELL medical advisory board to determine the next appropriate steps.*

*http://www.lctglobal.com/ntcell/ntcell/future-development
 
I have been watching LCT since joules mentioned it a while back. Both as a way to learn about medical trials and because I have a family history. Recently a close family member has been diagnosed.

Probably should of just donated the money to a charity, but instead I bought a couple of LCT shares, about $1000

Good example of how emotion that gets tied up with biotech, not a comment on LCT specifically, but seems like an industry in a prime position to take advantage of people
 
fiftyeight said:
I have been watching LCT since joules mentioned it a while back. Both as a way to learn about medical trials and because I have a family history. Recently a close family member has been diagnosed.

Probably should of just donated the money to a charity, but instead I bought a couple of LCT shares, about $1000

Good example of how emotion that gets tied up with biotech, not a comment on LCT specifically, but seems like an industry in a prime position to take advantage of people
Click to expand...

bio's are a black hole and investors are the event horizon

it's true that if there's a vested emotive reason to want the biotech to do well it's the opposite reason to buy in, always a punt either way.....LCT especially is not a business driven company, not yet anyways, owning the stock is a longterm EHR lottery ticket (albeit slightly higher odds!)

i had started an education thread over at sharecafe.com but they limited jpeg's so i gave it away, but, take a look, come interesting videos and science there....there's a lot more being accomplished in the PD space than most are aware both palliative and preventative and as one LCT board member says 'if you prevent the disease from getting worse extending the lifespan of the patient you have effectively found a cure'

in my late 50's i am more and more aware or people around me who have pre-parkinsons (parkinsonism) and pre-diabetese yet when i get into a discussion with them they are fatalistic without realising how much they get do for themselves to ameliorate (diabetese is proven simple to reverse now)

as we don't know direct causality we can know that there is clear evidence of paths to PD such as inflammation via dietary inputs, over-shunting of heme iron* across the blood brain barrier (needed for dopermagenic synthesis but maybe too much of a good thing) limiting inflammatory inputs and following a whole-food-plant-based diet may prove to be a pro-active benefit for most PD carriers, at least to have best optimal lifestyle

* https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2812924/
 
ROS

what is reactive oxidative stress ?

how can we prevent further deterioration of neural pathways and help in neuro-genesis

firstly it should be noted that only recently has science uncovered the relationship between dietary inputs as oxidative stress as an absolute, in other words, there is clear causality, a clear correlation both in triggering genetic activity and epigenetic activity, while we cannot fully control genetic triggering all the time we can have control over probability or triggering genetic switching, by restricting the markers that give genetic activation

it would be fair to say that not all genetically pre-disposed to PD actually trigger yet we do not know how to prove the case either way, yet, it is fair to assume that by restricting outliers and most often correlated inputs that we ourselves can control may give an edge on long-term outcomes, the question then is, can we control shorter term outcomes given diagnosis of PD? Can we adjust to or re-orient ourselves to what the body will allow given the decisions we do have control over regarding our dietary inputs?

if you have a broken arm do you keep playing cricket or wait for the mend to resume play?

ROS is borne for many thru diet
for example foods such as parmesan cheeses have oxydised cholesterol, the worse kind of cholesterol, even tho we now know cholesterol plays an important role as part of the whole anti-nitric oxide
anti-vascular dilation, the increase of free radicals without the contra input (via minerals/vitamins and trace elements) all upregulate stress the body would normally handle, this upregulation is a global phenom

exercise plays a big role, it appears that mitochondria requires constant work to be 'fully fit'

we may find out that the idea of PD being age-related is less to do with calendar age than it is to do with repetitive injury age, in other words, damage repeated over and over thru time is not a biologic input of nature, the opposite, antithetic by habit albeit uneducated (and probably) this lack of basic education on what we can control is the key to at least part control and getting an optimal outcome as best we can

there's a plethora of new sciences in containing PD affects in progress, if we perceive PD as a process rather than a disease, it's clear that we have more and more sciences uncovering how to restrict that process......and it is clear to me that we can have a simple and constant impact directly ourselves by begin fully self-informed on what we do on an epigenetic level, much work, sure, yet, the door is wide open......

so when i ask what is ROS, it is merely a prompt to research, as it is a single input, one of many, a sense of control that something can be done......again, the door is wide open
 
4 year implant annoc

easy to see the case for 80 v 40implant when LCT applies to reg body
....the outcomes probably way better than the 40 taken over the same period, which we dont need to wait for based on the phaseiib study

patient 1 is likely an ambassador with the result (so far)

it can be inferred this is a random outcome, sure, but the updrs also displays more time in + territory for all patients and (again) keeping in mind this was the 40implants

LCT annoc 4 year follup 210119.png
 
added to my long-winded holdings today, some bids expecting the safety board to approve next major study for PD to get the green light

the 80mg inplant should have enough data to get the nod

essentially this is the do-or-die period for the next few years regardless other pipeline ideas
 
Top